DiaMedica Therapeutics Inc.
DMAC
$5.67
-$0.13-2.24%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.04% | 7.39% | 27.93% | 32.38% | 31.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.33% | 28.92% | 34.41% | 51.90% | 46.09% |
| Operating Income | -24.33% | -28.92% | -34.41% | -51.90% | -46.09% |
| Income Before Tax | -20.73% | -20.13% | -24.69% | -41.69% | -36.52% |
| Income Tax Expenses | 53.57% | 53.57% | 53.57% | 53.57% | 0.00% |
| Earnings from Continuing Operations | -20.78% | -20.19% | -24.74% | -41.72% | -36.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.78% | -20.19% | -24.74% | -41.72% | -36.44% |
| EBIT | -24.33% | -28.92% | -34.41% | -51.90% | -46.09% |
| EBITDA | -24.32% | -28.92% | -34.44% | -51.95% | -46.15% |
| EPS Basic | 11.25% | 15.63% | 5.26% | -19.23% | -25.11% |
| Normalized Basic EPS | 11.32% | 15.67% | 5.27% | -19.29% | -25.23% |
| EPS Diluted | 11.25% | 15.63% | 5.26% | -19.23% | -25.11% |
| Normalized Diluted EPS | 11.32% | 15.67% | 5.27% | -19.29% | -25.23% |
| Average Basic Shares Outstanding | 32.70% | 42.52% | 33.52% | 22.64% | 11.64% |
| Average Diluted Shares Outstanding | 32.70% | 42.52% | 33.52% | 22.64% | 11.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
